New drug combo aims to shrink lung tumors before surgery
NCT ID NCT06268210
Summary
This study is testing whether a targeted drug called lazertinib, given alone or with standard chemotherapy before surgery, can better shrink tumors in people with early-stage lung cancer that has a specific genetic change (EGFR mutation). The goal is to see if this pre-surgery treatment helps surgeons remove more of the cancer and lowers the chance of it coming back. About 160 participants with operable lung cancer will be randomly assigned to receive one of the two treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.